Dermatology

Dupixent (dupilumab) is a non-immunosuppressive fully human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. According to data from Dupixent clinical trials, IL-4 and IL-13 are key drivers of type 2 inflammation, which is a major contributor to Atopic Dermatitis, Asthma, and Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP). There are two Dupixent dosings available (200 mg and 300 mg), each in the form of a pre-filled syringe. After an initial loading dosage, Dupixent is given every other week through an injection beneath the skin (subcutaneous Dupixent injection). It can be self-administered in a ...